Licaminlimab Biosimilar – Anti-TNFA mAb – Research Grade from ProteoGenix; catalogue PX-TA1679; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Licaminlimab Biosimilar, also known as Anti-TNFA mAb, is a research grade monoclonal antibody that has been developed to target and inhibit the activity of TNF-alpha (TNFA). TNFA is a cytokine that plays a crucial role in inflammation and immune response, and its dysregulation has been linked to various diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Licaminlimab Biosimilar has been designed to mimic the function of an existing anti-TNFA monoclonal antibody, with the aim of providing a more affordable and accessible therapeutic option for patients.
Licaminlimab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced using recombinant DNA technology and has been modified to be more similar to a human antibody. It is composed of two identical heavy chains and two identical light chains, each with a variable region that specifically binds to TNFA and a constant region that determines its effector function. The variable region of Licaminlimab Biosimilar has been engineered to have a high affinity for TNFA, allowing it to effectively bind and neutralize the cytokine.
Licaminlimab Biosimilar works by binding to TNFA, preventing it from interacting with its receptors on immune cells. This inhibits the downstream signaling pathways that lead to inflammation and immune response. By blocking the activity of TNFA, Licaminlimab Biosimilar helps to reduce inflammation and alleviate symptoms associated with TNFA-related diseases.
Licaminlimab Biosimilar is currently being investigated for its potential use in various diseases where TNFA plays a significant role. These include rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. In preclinical studies, Licaminlimab Biosimilar has shown promising results in reducing inflammation and disease severity in animal models of these diseases.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of joints. TNFA is a key mediator of inflammation in RA, and Licaminlimab Biosimilar has shown potential in reducing joint inflammation and improving symptoms in preclinical studies. Clinical trials are currently underway to evaluate its safety and efficacy in patients with RA.
Psoriasis is a chronic inflammatory skin disease that is also driven by TNFA. Licaminlimab Biosimilar has shown promising results in reducing skin inflammation and improving symptoms in preclinical studies. Clinical trials are currently ongoing to evaluate its potential as a treatment for psoriasis.
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the digestive tract. TNFA plays a significant role in the pathogenesis of IBD, and Licaminlimab Biosimilar has shown potential in reducing inflammation and improving symptoms in preclinical studies. Clinical trials are currently underway to evaluate its efficacy in patients with IBD.
Licaminlimab Biosimilar is a promising research grade monoclonal antibody that targets TNFA, a key cytokine involved in inflammation and immune response. Its structure and mechanism of action make it a potential therapeutic option for various TNFA-related diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Clinical trials are currently ongoing to evaluate its safety and efficacy in patients, and if successful, Licaminlimab Biosimilar could provide a more affordable and accessible treatment option for these diseases.
ProteoGenix catalogue number PX-TA1679. For research use only.
Target: Licaminlimab Biosimilar – Anti-TNFA mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Licaminlimab Biosimilar – Anti-TNFA mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
